|
PUS3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.33257857473745E-13 |
| Normal-vs-Stage2 |
1.25919999982571E-07 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
1.20390364344303E-11 |
| Stage1-vs-Stage2 |
9.722800E-01 |
| Stage1-vs-Stage3 |
1.421260E-03 |
| Stage1-vs-Stage4 |
2.602100E-02 |
| Stage2-vs-Stage3 |
3.268400E-02 |
| Stage2-vs-Stage4 |
9.350400E-02 |
| Stage3-vs-Stage4 |
8.716200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
2.87879999838481E-08 |
| Normal-vs-Asian |
1.61799999999213E-05 |
| Caucasian-vs-AfricanAmerican |
3.069000E-01 |
| Caucasian-vs-Asian |
2.600500E-02 |
| AfricanAmerican-vs-Asian |
2.404500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.69275704564598E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
8.975800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.97208915864167E-12 |
| Normal-vs-Age(41-60Yrs) |
3.66373598126302E-15 |
| Normal-vs-Age(61-80Yrs) |
5.18596277032657E-12 |
| Normal-vs-Age(81-100Yrs) |
9.79839999999399E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.035000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.911370E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.467800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.979800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.844200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.715200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.995000E-03 |
| Classical-VS-Follicular |
5.120200E-01 |
| Classical-VS-Other |
1.804980E-01 |
| Classical-VS-Normal |
4.68429961486549E-10 |
| Tall-VS-Follicular |
3.350300E-02 |
| Tall-VS-Other |
9.663800E-01 |
| Tall-VS-Normal |
1.2179146580138E-12 |
| Follicular-VS-Other |
4.007200E-01 |
| Follicular-VS-Normal |
2.09480000012974E-09 |
| Other-VS-Normal |
3.784900E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9817480989559E-13 |
| Normal-vs-N1 |
3.94129950898048E-10 |
| N0-vs-N1 |
4.672400E-01 |
|
|
